Skip to Content

Drugs.com is the most popular, comprehensive and up-to-date source of drug information online. Providing free, peer-reviewed, accurate and independent data on more than 24,000 prescription drugs, over-the-counter medicines & natural products.

Posted today in News for Health Professionals

Minor Birth Defects Up in Progeny of Female Gulf War Veterans

The odds of having a child with a minor birth defect are about five times higher for women veterans deployed during the Gulf War (DV) versus nondeployed women veterans (NDV), according to a study published in the April issue of the Journal of Occupational and Environmental Medicine. Marwan S. Shinawi, M.D., from Washington University in St. Louis, and...

Posted today in Medical

Half of Older Dialysis Patients Die Within a Year, Study Finds

The death rate for older Americans receiving dialysis for kidney failure may be nearly twice as high as widely thought, according to a new report. For the study, researchers looked at 391 Medicare patients, aged 65 and older, who started dialysis, in which a machine is used to remove toxins from the blood. Nearly 23% of the patients died within a...

Posted today in Medical

Is Peanut Allergy 'Immunotherapy' Causing More Harm Than Good?

The idea behind immunotherapy for peanut allergy is appealing in its simplicity: Ask a patient to eat tiny amounts of peanut every day, and over time their immune system will become desensitized to it. Unfortunately, this cure might be doing more harm than the allergy itself, a new evidence review suggests. People who undergo immunotherapy for their...

Posted 3 days ago in New Drug Approvals

FDA Approves Skyrizi (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis

AbbVie today announced that the U.S. Food and Drug Administration (FDA) approved Skyrizi (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.3 In clinical trials, Skyrizi produced high rates of durable skin clearance –...

Posted 3 days ago in News for Health Professionals

Risks, Benefits of Long-Term Drug Therapy for Osteoporosis Reviewed

Long-term osteoporosis drug therapy (ODT) reduces fracture risk in women but may increase risk for rare adverse events, and research gaps surround use of long-term drug therapies for osteoporotic fracture prevention, according to a review and position paper published online April 23 in the Annals of Internal Medicine. Howard A. Fink, M.D., M.P.H., from...

Posted today in Medical

Health Tip: Tick Removal

-- If you find a tick on your body, or that of a child or pet, remove the tick as soon as possible with a set of fine-tipped tweezers, says the U.S. Centers for Disease Control and Prevention. The CDC offers step-by-step instructions for removing a tick: Grasp the tick as close as possible to the skin with tweezers. Pull upward with steady, even pressure. After...

Posted today in News for Health Professionals

New App Aids Surgeons in Predicting Hernias After Abdominal Surgery

A new app can predict the likelihood that a patient will develop an incisional hernia (IH) following abdominal surgery (AS), according to a study presented recently at the annual meeting of the American Surgical Association, held from April 11 to 13 in Dallas. John P. Fischer, M.D., M.P.H., from the Perelman School of Medicine at the University of Pennsylvania...

Posted today in News for Health Professionals

CDC: Drinking Alcohol Not Uncommon Among Pregnant Women

Approximately one in nine pregnant women report drinking alcohol in the past 30 days, and among those, about one-third report binge drinking, according to research published in the April 26 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report. Clark H. Denny, Ph.D., from the CDC in Atlanta, and colleagues...

Posted today in News for Health Professionals

WHO: No More Than One Hour of Screen Time a Day for Young Children

Screen time for children younger than 5 should be limited to one hour a day, and those younger than 1 year should get no screen time at all, new World Health Organization guidelines say. The WHO's first guidelines on the topic are similar to recommendations from the American Academy of Pediatrics. Video chats should be the only screen time allowed for...

Posted today in News for Health Professionals

FDA Announces New Steps to Reduce Risks Tied to Surgical Staplers

The U.S. Food and Drug Administration this week announced three new efforts to protect patients from malfunctions, injuries, and deaths associated with the use of surgical staplers for internal use and implantable surgical staples. Last month, the agency issued a letter to health care providers informing them of an increasing number of medical device...

Read more news...

Recently added consumer and prescribing information: Evenity, Dovato, Duaklir Pressair, Mavenclad, Mayzent, Sunosi, Zulresso, Spravato, Jeuveau, Ultomiris

Posted in Blog

Worshipping The Wine (or Beer) God or Godess

For many Americans, alcohol is a big part of their life. No matter the occasion, from weddings to birthday parties, family gatherings to date nights, most assume alcohol will be available. In fact, more than 50% of people say they would enjoy a major event less if alcohol was prohibited. But at what point does […]

Posted in Blog

The Veneral Pest Returns

The history of syphilis makes interesting reading. For a start, there’s controversy about its origins. Some believe it to have been prevalent from at least 3000BC, whereas the more popular theory links its general introduction to the world to the return of the Columbus navigators from the New World in 1493. Regardless of its actual […]

Posted in Blog

The Feverish Pricing of MS Treatments

Towards the end of March, the FDA approved two new treatments for multiple sclerosis (MS): Mayzent (siponimod) and Mavenclad (cladribine). Both represent important breakthroughs for people with certain types of MS. But they come at a cost. The wholesale acquisition cost of Mayzent is $88,500 per year. Mavenclad is $99,500 annually. Even for those with […]

See more blog posts or follow us on twitter.